The pharmaceutical supply chain is experiencing a critical transition moment. While regulatory compliance timelines have dominated industry conversations, a more immediate challenge is emerging from pharmacy receiving docks across the country: the infrastructure meant to ensure drug traceability is breaking down at the data level.

The Gap Between Compliance and Operational Reality

Serialization mandates promised a future where every pharmaceutical product could be tracked seamlessly from manufacturer to patient. The vision was elegant—standardized data formats, universal identifiers, and automated verification systems working in harmony across trading partners.

What’s actually happening tells a different story.

Pharmacies implementing EPCIS-based receiving workflows are discovering that technical compliance doesn’t guarantee operational success. The problems aren’t theoretical—they’re manifesting daily in receiving departments where staff encounter data that doesn’t match physical inventory, transaction records that arrive hours after shipments, and validation failures that have nothing to do with product authenticity.

Five Critical Failure Points in EPCIS Implementation

1. Product Identification Breakdown

The foundation of serialized tracking depends on accurate product identifiers—GTINs, NDCs, lot numbers, and package hierarchies. When these fundamental data elements contain errors or inconsistencies between trading partners, the entire verification chain collapses.

Pharmacies report scanning valid products only to see system rejections because supplier master data doesn’t align with their internal catalogs. The product is legitimate, the serial number is authentic, but mismatched identifiers create false negatives that force manual intervention.

This isn’t a rare edge case. It’s becoming a routine friction point that slows receiving operations and requires staff to perform investigative work they weren’t trained to do.

2. Location Identifier Confusion

Global Location Numbers serve as the addressing system for EPCIS transactions. When GLN configurations contain errors—wrong receiver identifiers, outdated location codes, or misrouted endpoints—data becomes disconnected from physical shipments.

The symptoms are particularly frustrating: suppliers confirm transmission while pharmacies see nothing in their systems. The data exists somewhere in the supply chain network, but routing failures make it operationally invisible at the point where it’s needed most.

Some pharmacies are discovering they’re using multiple GLNs inconsistently, or that legacy system migrations left outdated identifiers active in supplier databases. These configuration problems create persistent data delivery failures that require systematic investigation to resolve.

3. Standards Implementation Variability

GS1 provides detailed specifications for EPCIS event structure, but implementation quality varies significantly across suppliers. Some organizations interpret standards loosely, structure aggregation events incorrectly, or omit required data elements that downstream partners expect.

The result is files that technically validate against schema but fail operational use cases. Pharmacies can receive EPCIS documents that don’t contain sufficient information to verify shipment contents or properly update inventory systems.

This creates a particularly difficult problem: suppliers believe they’ve fulfilled their obligations by transmitting data, while pharmacies can’t actually use that data to complete receiving workflows. The gap between technical compliance and functional utility becomes a source of ongoing operational friction.

4. Synchronization Timing Failures

Supply chain velocity often outpaces data transmission. Physical shipments arrive at pharmacy receiving docks before corresponding EPCIS transactions reach verification systems. This temporal mismatch forces immediate operational decisions: should staff hold product pending data arrival, or proceed with receiving and reconcile later?

Neither option is ideal. Holding shipments creates inventory delays and storage challenges. Receiving without data verification undermines the entire purpose of serialized tracking and creates compliance risk.

The timing problem reveals a fundamental assumption gap—system designers expected data to precede or accompany physical goods, but logistics reality doesn’t always cooperate with that model.

5. Aggregation Logic Errors

When products are packed in cases and cases are loaded on pallets, aggregation events should create hierarchical relationships between parent and child serial numbers. Errors in this logic—missing relationships, incorrect associations, or incomplete hierarchies—break the connection between what was shipped and what can be verified upon receipt.

Pharmacies attempting to verify case contents may find EPCIS data that references the case serial number but doesn’t properly enumerate individual unit serials. Or they encounter aggregation events that don’t match physical packaging configurations, forcing manual verification of every unit.

The Investigation Burden Shifts to Pharmacy Operations

When any of these data failures occur, pharmacies inherit the problem-solving burden. Receiving staff must transition from routine inventory processing to diagnostic investigation:

• Comparing physical product attributes against multiple data sources
• Contacting suppliers to request corrected information or clarification
• Documenting discrepancies for compliance and audit purposes
• Making risk-based decisions about product quarantine or release
• Escalating unresolved issues through internal and external channels

This investigative work requires time, expertise, and clear decision frameworks that many pharmacy operations weren’t designed to provide. The efficiency gains promised by automated serialization verification evaporate when data quality problems force manual intervention.

Building Resilient Exception Management Processes

The emerging reality of DSCSA implementation demands that pharmacies develop robust exception handling capabilities. Reactive troubleshooting isn’t sustainable—organizations need systematic approaches to data quality problems.

Structured Investigation Protocols

When receiving workflows encounter data mismatches, staff need clear diagnostic procedures:

For identifier mismatches: Systematically verify each data element (GTIN, NDC, lot, expiration, serial) against all available sources (EPCIS transaction, purchase order, invoice, product catalog). Identify which specific element is inconsistent and whether the error originates from supplier data or internal system configuration.

For missing transaction data: Establish search procedures using multiple reference points—purchase order numbers, shipment identifiers, SSCC codes, and individual product serials. Determine whether data was never transmitted, was routed incorrectly, or is delayed in processing.

For GLN routing failures: Verify that all trading partners have current, accurate location identifiers. Confirm that production systems (not test environments) are being used. Validate that supplier sender GLNs and pharmacy receiver GLNs are correctly configured in all systems.

Supplier Communication Frameworks

Effective issue resolution requires clear communication channels with trading partners. Pharmacies should establish protocols for:

• Providing specific, actionable information when reporting problems (exact GTINs, serial numbers, shipment references, and error descriptions)
• Setting expectations for response timeframes based on operational impact
• Documenting supplier responses and corrective actions
• Tracking recurring issues that indicate systematic problems rather than isolated errors

Product Disposition Decision Trees

Data quality problems force immediate decisions about physical inventory. Pharmacies need predefined criteria for:

• When product should be quarantined pending data resolution
• What level of data verification is required before releasing inventory for dispensing
• How long product can be held before alternative disposition is required
• Who has authority to make release decisions under various scenarios

These decision frameworks should balance compliance requirements, operational needs, and patient access considerations.

Pre-Implementation Validation: The Critical Step Most Organizations Skip

Perhaps the most important lesson emerging from early DSCSA implementation experiences is this: assuming supplier readiness is a costly mistake.

Pharmacies that conduct thorough pre-implementation testing with each trading partner identify and resolve problems before they impact live operations. Those that skip validation discover issues only when receiving workflows fail under production conditions.

Effective validation testing should simulate real operational scenarios:

• Complete end-to-end transactions from supplier systems through pharmacy receiving workflows
• Timing variations that reflect actual logistics patterns, not idealized same-day scenarios
• Exception conditions including partial shipments, returns, and product substitutions
• Volume stress testing that reveals performance issues hidden in small-scale pilots

Testing should explicitly verify that GLN routing works correctly, that EPCIS data arrives with sufficient lead time, that product identifiers match across systems, and that aggregation hierarchies accurately represent physical packaging.

Organizations that invest in comprehensive validation avoid the much higher cost of troubleshooting problems in live production environments while managing operational disruptions and compliance risk.

The Operational Maturity Challenge

DSCSA implementation is revealing which organizations treat supply chain data as a strategic operational capability versus those that view it as a compliance checkbox.

Pharmacies that are succeeding share common characteristics:

• They’ve invested in staff training that goes beyond basic system operation to include diagnostic troubleshooting
• They’ve documented detailed procedures for exception scenarios, not just happy-path workflows
• They’ve established clear accountability for data quality issues and supplier relationship management
• They’ve built monitoring capabilities that identify emerging problems before they become operational crises

Organizations struggling with implementation typically lack these capabilities. They’re attempting to manage complex data quality problems with ad hoc processes, unclear accountability, and insufficient documentation.

As serialized transaction volumes increase, this operational maturity gap will become increasingly consequential. The pharmacies that develop disciplined exception management capabilities now will maintain operational efficiency. Those that continue relying on reactive troubleshooting will face escalating disruption.

Documentation as Operational Infrastructure

One of the most overlooked aspects of DSCSA readiness is procedure documentation. When data quality problems occur—and they will—staff need immediate access to clear guidance about investigation steps, communication protocols, and decision criteria.

Comprehensive standard operating procedures should address:

• Specific diagnostic steps for each category of data failure
• Supplier contact information and escalation paths
• Documentation requirements for compliance and audit purposes
• Product disposition criteria and approval workflows
• System-specific troubleshooting for the pharmacy’s technology platform

This documentation serves multiple purposes: it enables consistent responses to exceptions, supports staff training, provides audit evidence of systematic quality management, and creates organizational knowledge that survives staff turnover.

Pharmacies serious about operational readiness are building these procedure libraries now, before exception volumes overwhelm their ability to respond effectively.

The Path Forward

The pharmaceutical supply chain is in the middle of a fundamental transformation. The technical infrastructure for serialized tracking is largely in place, but the operational disciplines required to make that infrastructure function reliably are still developing.

Pharmacies can’t control supplier data quality or standards implementation consistency across their trading partner network. What they can control is their own operational readiness—their ability to identify problems quickly, investigate efficiently, communicate effectively, and make sound decisions when data fails to meet expectations.

The organizations that treat DSCSA as an operational capability challenge, not just a compliance requirement, will navigate this transition successfully. Those that underestimate the operational complexity will find themselves struggling with persistent disruptions that impact both efficiency and patient service.

The question isn’t whether data quality problems will occur—early implementation experience makes clear they will. The question is whether pharmacy operations will be prepared to handle them systematically when they do.

Get DSCSA Compliant:
Whether you’re a traditional pharmacy or a med spa preparing for new regulations, the time to act is now. The November 2026 deadline is approaching, and compliance takes time to implement properly.

Need help getting DSCSA compliant? Contact TrackTraceRX for affordable solutions designed for independent pharmacies and small healthcare businesses.

About the Author: Christian is a pharmaceutical compliance specialist focused on helping independent pharmacies and healthcare businesses navigate DSCSA requirements. For more information about DSCSA compliance solutions, visit www.tracktracerx.com or call 1-321-418-7147.